Thyroid cancer cell lines: An overview

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Saiselet, Manuel ^a   Floor, Sébastien ^a   Tarabichi, Maxime ^a   Dom, Geneviève ^a   Hébrant, Aline ^a   van Staveren, Wilma C G ^a   Maenhaut, Carine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

BCPAP; Cancer; Cell line; FTC133; Mutation; Thyroid; TPC1; WRO

Indexed keywords

EID: 84874442927     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00133     Document Type: Article

References (35)

1. Breitling, R., Armengaud, P., Amtmann, A., and Herzyk, P. (2004). Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573, 83-92.
2. Burrows, N., Resch, J., Cowen, R. L., von, W. R., Hoang-Vu, C., West, C. M., et al. (2010). Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr. Relat. Cancer 17, 61-72.
3. Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., and Boccuzzi, G. (2010). Emerging molecular therapies of advanced thyroid cancer. Mol. Aspects Med. 31, 215-226.
4. Challeton, C., Branea, F., Schlumberger, M., Gaillard, N., de Vathaire, F., Badie, C., et al. (1997). Characterization and radiosen-sitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 163-169.
5. Estour, B., Van Herle, A. J., Juillard, G. J., Totanes, T. L., Sparkes, R. S., Giuliano, A. E., et al. (1989). Characterization of a human fol-licular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 57, 167-174.
6. Fabien, N., Fusco, A., Santoro, M., Barbier, Y., Dubois, P. M., and Paulin, C. (1994). Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73, 2206-2212.
7. Garcia-Rostan, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J., et al. (2005). Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 65, 10199-10207.
8. Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., et al. (2005). Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24, 6646-6656.
9. Goretzki, P. E., Frilling, A., Simon, D., and Roeher, H. D. (1990). Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res. 118, 48-63.
10. Harlin, H., and Gajewski, T. F. (2008). Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr. Protoc. Cytom. 43, A.3C.1-A.3C.7.
11. Hébrant, A., Dom, G., Dewaele, M., Andry, G., Trésallet, C., Leteurtre, E., et al. (2012). mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS ONE 7:e37807. doi: 10.1371/journal.pone.0037807
12. Hou, P., Bojdani, E., and Xing, M. (2010). Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J. Clin. Endocrinol. Metab. 95, 820-828.
13. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
14. Ito, T., Seyama, T., Iwamoto, K. S., Hayashi, T., Mizuno, T., Tsuyama, N., et al. (1993). In vitro irradiation is able to cause RET onco-gene rearrangement. Cancer Res. 53, 2940-2943.
15. Kondo, T., Ezzat, S., and Asa, S. L. (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306.
16. Lacroix, L., Mian, C., Barrier, T., Talbot, M., Caillou, B., Schlumberger, M., et al. (2004). PAX8 and peroxi-some proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur. J. Endocrinol. 151, 367-374.
17. Liu, D., Liu, Z., Jiang, D., Dackiw, A. P., and Xing, M. (2007). Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J. Clin. Endocrinol. Metab. 92, 4686-4695.
18. Meireles, A. M., Preto, A., Rocha, A. S., Rebocho, A. P., Maximo, V., Pereira-Castro, I., et al. (2007). Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 17, 707-715.
19. Montanaro, L., Trere, D., and Derenzini, M. (2012). Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. Biochim. Biophys. Acta 1825, 101-110.
20. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., et al. (2003). Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393-4397.
21. Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., et al. (2010). B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl. Acad. Sci. U.S.A. 107, 10649-10654.
22. Palona, I., Namba, H., Mitsutake, N., Starenki, D., Podtcheko, A., Sedliarou, I., et al. (2006). BRAFV600E promotes inva-siveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147, 5699-5707.
23. Ribeiro, F. R., Meireles, A. M., Rocha, A. S., and Teixeira, M. R. (2008). Conventional and molecular cyto-genetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer 8:371. doi: 10.1186/1471-2407-8-371
24. Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., et al. (2009). Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885-4893.
25. Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., et al. (2008). Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331-4341.
26. Sipos, J. A., and Mazzaferri, E. L. (2010). Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. (R. Coll. Radiol.) 22, 395-404.
27. Tanaka, J., Ogura, T., Sato, H., and Hatano, M. (1987). Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 161, 62-72.
28. van Staveren, W. C., Solis, D. W., Delys, L., Duprez, L., Andry, G., Franc, B., et al. (2007). Human thyroid tumor cell lines derived from different tumor types present a common dedifferen-tiated phenotype. Cancer Res. 67, 8113-8120.
29. Van Staveren, W. C., Solis, D. W., Delys, L., Venet, D., Cappello, M., Andry, G., et al. (2006). Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigene-sis. Proc. Natl. Acad. Sci. U.S.A. 103, 413-418.
30. Van Staveren, W. C., Solis, D. Y., Hebrant, A., Detours, V., Dumont, J. E., and Maenhaut, C. (2009). Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta 1795, 92-103.
31. Wang, H., Mannava, S., Grachtchouk, V., Zhuang, D., Soengas, M. S., Gudkov, A. V., et al. (2008). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27, 1905-1915.
32. Xing, M. (2010). Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell Endocrinol. 321, 86-93.
33. Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., and Prinz, R. A. (2003). High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567.
34. Yeung, S. C., She, M., Yang, H., Pan, J., Sun, L., and Chaplin, D. (2007). Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92, 2902-2909.
35. Zang, S., Guo, R., Zhang, L., and Lu, Y. (2007). Integration of statistical inference methods and a novel control measure to improve sensitivity and specificity of data analysis in expression profiling studies. J. Biomed. Inform. 40, 552-560.